Courage Against Cancer emphasizes the importance of distinguishing between the registered trial NCT05318469 and the controversial Hulscher et al. 2026 study. The former aims to assess ivermectin’s safety and efficacy for metastatic triple-negative breast cancer under rigorous oversight, while the latter lacks validated endpoints and ethical scrutiny. Valid results are pending.
Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Research & Critical Analysis Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Health & Wellness Hulscher Study Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company
The Only Registered Human Ivermectin Oncology Trial (NCT05318469): What Is Actually Known
